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Abstract 
Curing HIV-1 Infection via in vitro ultra-sensitive modification of Human Immunodeficiency Virus-1 (HIV-1) 
uninfected CD4
+
 cells is a promising hypothetical procedure that links different established clinical/laboratory 
tools (methods) and channeling them towards a clinical trial to achieve the ultimate goal of curing HIV-1 
infection. The In vitro ultra-sensitive chemical modification of HIV-1 uninfected CD4
+
 cells using selected anti-
viral agents towards curing HIV-1 infection entails a six step clinical/laboratory procedure. Isolation/purification 
of HIV-free CD4
+
 cells is the first step of this therapeutic procedure. In vitro CD4
+
 cell expansion/culture, ultra-
sensitive chemical modification, inhibition/suppression of CD4
+
 cell proliferation, administration of chemically 
modulated cells to HIV-infected patient, monitoring/maintaining the physiological/biochemical processes under 
intensive care make up the other steps of this procedure consecutively. The milestones in this therapeutic method 
include increased bioavailability, minimum dosage, minimal or no side effects, shorter duration of treatment, 
mop-up of free plasma virions. The principal reason for this adopted method is that, the therapy overcomes the 
limitations posed by the current methods of managing HIV-1 infection using anti-retrovirals. 
Keywords: Curing, CD4
+
 cells, HIV-1 infection, antiviral, side effect, modification 
 
1.0 Introduction 
Viruses are the most notorious of all pathogenic organisms of humans, and we lack foolproof anti-viral therapies 
against them
 
(Shailendra et al., 2009). So far, most of the antiviral agents presently employed in managing HIV-
1 infection come with side effects that to some extent offset their therapeutic benefits (Monica, 2009). HIV-1 
infection when untreated results in a progressive destruction of the immune system resulting in acquired 
immunodeficiency syndrome (AIDS) (Boasso et al. 2009) defined as the presence of HIV infection with a CD4 
cell count less than 200 cells/mm
3
 (Ali, 2007). HIV/AIDS continues to be a major and one of the leading 
diseases with an estimated 2.7 million new infections in 2007 and an estimated 2 million deaths was recorded 
following HIV-related illnesses in the same year (Nick, 2009). HIV was recovered first from infected cluster of 
differentiation positive (CD4
+
) lymphocytes and was considered a T-lymphotropic virus (Levy, 1993). 
Subsequent studies indicated a wider host range for this virus, including macrophages, other hematopoietic cells, 
CD4-negative human fibroblasts and brain-derived cells (Levy, 1993). However, replication occurs at its highest 
titer in CD4
+
 lymphocytes (Shenbei et al. 1995). The CD4 T (helper) are the coordinators of the body's immune 
response. The “CD” or cluster of differentiation is a protein expressed on the surface of the cells of the 
hematopoietic system and within hours of exposure to HIV, CD4
+
 T lymphocytes are found to be infected 
showing active viral replication (Alan et al. 1996). Millions of CD4
+
 T lymphocytes may be destroyed every day, 
eventually overwhelming the immune system's regenerative capacity. Although differences exist in the range of 
values for normal CD4 count obtained from various laboratories/clinics, a normal CD4 count has a range of 600–
1,500 cells/mm
3
. In HIV-1 infection, CD4
+
 T cells specific for HIV-1 are infected by the virus at higher 
frequencies than other memory CD4
+
 T cells. HIV-1 specific CD4
+
 T cells are barely detectable in most infected 
individuals and the corresponding CD4
+ 
T cells exhibit an immature phenotype compared to both 
cytomegalovirus (CMV)-specific CD4
+
 T cells and other memory CD4
+
 T cells (Jason et al. 2006). The in vitro 
ultra-sensitive modification of HIV-1 uninfected CD4
+
 cells using antiviral agents is aimed at presenting a step 
by step clinical/laboratory procedure as part of a cycle of repeated process towards curing HIV-1 infection. 
 
1.1 Milestones in this therapeutic procedure 
It’s vital to know that most of the side effects of antiretroviral medications originate from the dosage and route of 
administration. Some of the most notable side effects of antiretroviral drugs are diarrhoea, nausea and vomiting, 
rash, lipodystrophy, lipid abnormalities and myocardiac infarction. A study review has found that 60 percent of 
people on antiretroviral drugs report diarrhoea (MacArthur et al. 2012), most especially during the first few 
weeks of treatment and can reduce appetite (AVERTing HIV and AIDS, 2014). This may generate more serious 
problems such as pancreatitis or lactic acidiosis. Rashes often appear as a side effect of antiretroviral treatment 
and often itchy but are usually harmless and short-lived. Lipodystrophy involves losing or gaining body fat, 
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often in ways that can be disfiguring and may be in the form of losing fat on the face, arms, legs and buttocks, 
resulting in sunken cheeks, prominent veins on the limbs, and shrunken buttocks (AVERTing HIV and AIDS, 
2014). HIV positive patients taking antiretroviral treatment commonly have high levels of a lipid called LDL 
cholesterol, low levels of HDL cholesterol, and high levels of triglyceride in the blood (AVERTing HIV and 
AIDS, 2014). In 2008, a large investigation called the D: A: D study reported that the use of the NRTI abacavir 
was associated with a higher risk of myocardial infarction compared to other drugs in the same class (D: A: D 
Study Group et al. 2008). 
Bioavailability is a subsection of absorption of medication; the portion of an administered dosage of 
unaltered drug that gets to the systemic circulation for further metabolism. When a medication/drug is 
administered intravenously, its bioavailability is 100% (Griffin, 2009). However, when a medication is 
administered via other routes (most especially orally), its bioavailability generally decreases due to incomplete 
absorption and first-pass metabolism
 
(Mukonzo et al. 2011). For polar compounds of which antiretroviral agents 
are a part of, the major factor restricting their entry lies in the tight junctions that occlude the paracellular 
pathway across these barriers. In addition, influx and efflux transport systems, or metabolic processes active in 
both capillary endothelial cells and choroid plexus epithelial cells, can greatly change the bioavailability of a 
drug in one or several compartments of the CNS (Strazielle & Ghersi-Egea, 2005). Other major factors that may 
affect drug availability are Enzyme Induction and Inhibition, Enzyme Polymorphisms, and Disease States 
(Romil, 2011). The physicochemical factors affecting drug absorption include the pH-partition hypothesis on 
drug absorption, ionization and pH at absorption site, lipid solubility (Wolters, 2012). 
Antiretroviral agents mostly exert their toxic, carcinogenic, allergic and mutagenic effects by going to 
other cells, tissues or organs that are not the target. The in vitro Ultra-sensitive Modification of HIV-1 
Uninfected CD4
+
 Cells however, is set out to boycott all these limitations since drug delivery is in vitro. The 
highest level of drug targeting expressed here will reduce all side effects to the minimum. This is evident in the 
minimal dosage of anti-viral agent, and the duration of treatment will definitely be shorter. The patient might be 
cured in a matter of days or few weeks. A remarkable feature of this method is also the mop-up of free plasma 
virions. 
 
1.2.1 Isolation/purification of HIV-1 uninfected CD4
+
 cells (step 1) 
Human CD4
+
 lymphocytes are heterogeneous and can be distinguished by cell surface proteins that denote 
adhesion and activation antigens. This step of the procedure is aimed at isolating a set of HIV-1 uninfected cells 
from the source. Choice of HIV-free CD4
+
 cells donor could be presumptuously achieved in two ways. 
(a)    The beneficiary (HIV infected patient) will be the donor. Making this choice will require  a series of 
clinical tests to distinguish HIV infected CD4
+
 cells from non-infected ones. 
(b) The donor will be HIV-seronegative individual and must not necessarily be the  beneficiary. 
Compatibility check to ensure a close match between the donor and the  recipient should be ordered to minimize 
immunological complications. 
The advantage of option (a) over (b) is that complications that could probably arise from immunological 
responses of self against non-self (foreign body) is eliminated.  
A number of methods can be employed in achieving the isolation and purification of uninfected CD4
+
 
cells. Nakamura et al. demonstrated that, Human PBMC isolation is achievable by immunomagnetic beads 
through Ficoll/Conray gradient centrifugation 
[18]
. Thereafter, the separation of CD4
+
 T cells can be performed 
by a positive selection technique as reported by Gaudernack et al. using sheep anti-mouse IgG-coated 
immunomagnetic beads (Gaudernack et al. 1986). The purity of CD4
+
 T cells in recovered cells was over 98%. 
The isolated CD4+ T cells consisted of 46% of CD45RO and 54% of CD45RA. Through adherence to plastic, 
CD4
+
 Peripheral blood mononuclear cells (PBMC) could also be obtained by Ficoll-Hypaque separation of 
peripheral blood buffy coat as well as Peripheral blood macrophages from these PBMC (Homsy et al. 1989).  
Invitrogen life technologies provides a viable method of a high yield of pure CD4
+
 Isolation from whole 
blood, buffy coat, mononuclear cells (MNCs), or bone marrow (Life Technologies, 2011). Invitrogen Corporation 
also provides a viable negative cell isolation technology for isolating pure and untouched human CD4
+
 T cells 
(Invitrogen Corporation, 2008) where an antibody mix is added to bind to non-CD4
+
 T cells (B cells, NK cells, 
monocytes, platelets, dendritic cells, CD8
+
 T cells, granulocytes, and erythrocytes). Dynabeads® then bind to 
these antibody-labeled cells and with the aid of a DynaMag™ magnet, the bead-bound cells are captured and 
discarded.  
Miltenyi offers another method for the purification of cells from several organisms including humans, 
non-human primates, rat and mice. This magnetic bead-based cell separation allows for either positive selection 
(or cell depletion) as well as negative selection. Employing this standard protocol for the purification of cells 
guarantees 96% pure CD4
+
 cells (Matheu & Cahalan, 2009).  
James, LaFond, Durinovic-Bello and Kwok, provided a detailed description of a method of isolating CD4
+
 cells 
from PBMC, in which blood is collected in syringes or blood tubes and anti-coagulated with heparin (1:50 ratio) 
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to prevent clotting (James et al. 2009). Expected yield is about 1×10
6
 PBMC per mL of blood – about 40% of 
which will be CD4
+
 T cells. Thereafter, the succeeding steps in the isolation process are carried out. The cell 
counts at the end of the isolation process will dictate the number of wells used for the expansion culture step 
when required. 
 
1.2.2 In-vitro CD4+ cell culture/expansion (step 2) 
It has been demonstrated that the culture of peripheral blood mononuclear cells (PBMC) in the presence of 
interleukin 2 (IL-2) caused the predominant growth of CD8+ T cells (Taylor et al. 1985)
 
and the selective in 
vitro growth of CD4+ T cells in the presence of IL-2 has been considered to be difficult. The different IL-2 
responsiveness of CD8+ and CD4+ T cells was demonstrated to be derived from their differential expression of 
p75 IL-2 receptor (IL-2R) (Nakamura et al. 1991). It has been however, demonstrated that stimulation of 
FACStar-sorted CD4+ T cells with immobilized OKT-3 monoclonal antibody (mAb) induced p75 IL-2R 
expression and IL-2 responsiveness of CD4+ T cells. Moreover, CD4+ T cells have demonstrated to display both 
IL-2 producing activity and bispecific antibody-directed antitumor activity (Nishimura et al. 1992). A simple 
method for the isolation and expansion of CD4+ T cells is described by a simple method for the generation and 
expansion of CD4+ T cells with both helper and killer functions in the presence of immobilized anti-CD3 mAb 
plus IL-2 [18]. The large-scale expansion of activated CD4+ helper/killer T cells was achieved using a 
concentrated rotary tissue-culture (CRTC) bag alongside the in vitro targeting of the CD4+ helper/killer T cells 
by means of anti-CD3 x anti-c-erbB-2 bispecific antibody (BsAb). Large-scale expansion of CD4+ T cells can 
be performed by culturing with immobilized OKT-3 mAb plus rIL-2 (Nakamura et al. 1992). This large scale 
culture yielded an approximate 3000-fold increase in cell numbers after 16 day-culture. Dynal Biotech provides 
a putative efficient method of cell culture. Over 1000 fold expansion of T cells can be achieved in 12 days when 
naïve T cells are incubated with Dynabeads® CD3/CD28 T Cell Expander (Dynal  Biotech, 2002). James, 
LaFond, Durinovic-Bello and Kwok, provided a description of a method of expansion culture of CD4+ cells in 
vitro that follows the isolation of CD4+ cells from Peripheral blood mononuclear cell (PBMC) (James et al. 
2009) as described in the previous section. 
 
1.2.3 Ultra-sensitive Chemical modification of the clone using antiviral agent (step 3) 
The in vitro chemical modification involve incubating the clone of CD4
+
 cells in a physiological medium 
containing the right concentration of the anti-viral agent. The anti-viral agent is transported across the membrane 
to the site of action. The therapist should be able to use available newer, more potent, and less toxic antiretroviral 
(ARV) agents for this trial. Effective concentration (EC50 and EC90) at which HIV-1 replication is inhibited in 
the CD4+ cell must be established. The drug delivery system employed plays a vital role in controlling the 
pharmacological effect of the drug as it can influence the pharmacokinetic profile of the drug, the rate of drug 
release, the drug bioavailability, the site and duration of drug action and subsequently the side effect profile 
(Yvonne & Thomas, 2010). We therefore, project an in vitro delivery of the therapeutic antiviral agents in to the 
clone of CD4+ cells prior to administration of the CD4
+
 cells to the patient.  This will ensure an optimal drug 
delivery system in which the active drug is available at the site of action at the correct time and duration. 
 
1.2.4 Inhibition/suppression of CD4
+
 cell proliferation in the HIV-infected patient (step 4) 
The patient is placed under intensive care in a sterile environment. This is because the suppression of the activity 
of the CD4
+
 cells that mediate the cell-mediated immunity will make the patient vulnerable to other infectious 
organisms. The sole aim of suppressing the further production of more CD4
+
 cells is to halt the production of 
cells that lack the therapeutic modification described in the step above, which may serve as factories for HIV-1 
proliferation. A number of immunosuppressive drugs are available and may include corticosteroids, purine 
pathway inhibitors such as azathioprine and mycophenolate, pyrimidine pathway inhibitors, immunophilin-
binding agents and alkylating agents (Lee & Andrew, 2012). 
 
1.2.5 Administration and activation of the chemically modulated clone to the infected patient (step 5) 
The route of administration of the in vitro chemically-modulated set of CD4+ cells will be intravenous: small 
volumes can be given as a single dose whereas larger volumes can be given by infusion. A big question here is 
about the quantity of chemically modified CD4
+
 cells that will be administered to patients. HIV-1 replication in 
vivo occurs continuously at high rates (Alan et al. 1996) and according to Alan et al. the estimated average total 
HIV-1 production was 10.3 × 10
9
 virions per day. Alan et al. used a mathematical model to explain HIV-1 
dynamics in vivo (Alan et al. 1996). A potent HIV-1 protease inhibitor, ritonavir was administered orally to the 
patients (600 mg twice daily) through the period of investigation and the result of the research is an essential 
component of the bed rock of this proposed therapy (Alan et al. 1996). Administered ultra-sensitive chemically 
modified CD4+ cells are readily available to be infected by free virions, but will however, be preceded by the 
commencement of treatment with a potent HIV-1 protease inhibitor such as ritonavir or more potent ones. Cell 
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death could be induced at this stage in the administered cell 2.6 days (62 hours) after administration as a 
therapeutic measure. HIV-1 generation time-defined as the time from release of virion until it infects another cell 
and causes the release of a new generation of new particles is 2.6 days (Alan et al. 1996). Therefore, in order to 
halt any likelihood of release of new generation of viral particles that are products of the complete life cycle of 
virions that survived the effect of the anti-viral agent such as alkylating antineoplastic agent as well as the 
protease inhibitor, we induce cell death in the administered modified cells. This is then followed by the 
administration of a new dose of modified cells. However, the minimum duration of HIV-1 in vivo is 1.2 days (28 
hours) on average (Alan et al. 1996).  
Knowing that the estimated average life span of productively infected cells is 2.2 days (52 hours) (Alan 
et al. 1996), a new dose of the modified cells can be administered after 52 hours. We presume that after about 52 
hours, the previously administered dose of modified cells would have been killed by invaded viruses. It is 
important to note that this method is an alternative to the first method (induction of cell death after 62 hours) 
described in the previous paragraph. Though there are a lot of irregularity in getting a universally regular normal 
range of values for CD4 count, we 600-1500 cells/mm
3
 is often used by many standard laboratories. The quantity 
of CD4+ cells to be administered to the patient will depend on the stage of the infection in the patient and the 
outcome of the routine test at regular intervals described previously. However, we propose a formula as depicted 
below that could make the work of the therapist easier. 
    /	 
 is the small volume of choice taken from the stock of CD4+ culture medium stock 
	 is the number of CD4+ cells gotten from a CD4 count performed on  
 is the volume of CD4+ cells medium to be administered to the patient 
 is the number of CD4 cells to be administered to patient. 
 is to be decided by the therapist after a CD4 count is carried out for the patient. However, there are there are 
two alternatives here. The therapist could decide to administer a complete volume that will supply a complete 
number of CD4 count regardless of the level of the CD4 cells in the patient before administration. Alternatively, 
with regards to the level of CD4 cells in the patient, the therapist could administer a volume that will make up 
the initial level to the normal level. 
 
1.2.6 Monitoring and maintaining the physiological/biochemical processes (step 6) 
In addition to the series of other successive routine clinical tests, HIV RNA (viral load) and CD4 T lymphocyte 
(CD4) cell count will be the two surrogate markers of treatment responses and HIV disease progression. Viral 
load is a marker of response to ART to provide prognostic information about the probability of disease 
progression (Murray et al. 1999). Viral load is the most important indicator of initial and sustained response to 
ART. Several systematic reviews of data from clinical trials involving thousands of participants have established 
that decreases in viral load following initiation of ART are associated with reduced risk of progression to AIDS 
or death (Thiebaut et al. 2000). There are a number of recommendations on the frequency of viral load 
monitoring depending on situations such as, initiation of ART or modification of therapy because of virologic 
failure, virologically suppressed patients in whom ART was modified because of drug toxicity or for regimen 
simplification, patients on a stable suppressive ARV regimen, and patients with suboptimal response. This 
review however, suggests that the frequency will be determined by the result of the previous test while the 
patient is kept under intensive care. The CD4 count is the most important laboratory indicator of immune 
function in HIV-infected patients. The CD4 cell count provides information on the overall immune function of 
an HIV-infected patient. It is also the strongest predictor of subsequent disease progression and survival 
according to findings from clinical trials and cohort studies (Egger et al. 2002). Splenectomy (Bernard et al. 
1998) or co-infection with human T-lymphotropic virus type I (HTLV-1) and other factors may cause 
misleadingly elevated CD4 counts. Alpha-interferon may reduce the absolute CD4 count without changing the 
CD4 percentage (Casseb et al. 2007). In all these settings, CD4 percentage remains stable and may be a more 
appropriate parameter to assess a patient’s immune function. These tests are critical in establishing thresholds for 
the initiation, continuation and discontinuation of the administration of chemically modified CD4+ cells. These 
tests should be done at initiation of therapy and at regular intervals as well as at other intervals considered fit by 
the therapist and may not necessarily be regular. It’s vital to note that the patient is kept under intensive care in a 
sterile environment throughout the trial. 
 
Conclusion 
The side effects that accompany most of the antiretroviral agents sometimes outweigh their therapeutic effects. 
The stress of repeated regimented dosage as well as the chronic duration of treatment can be tedious for the 
patient. It is therefore pertinent that we look for a faster, more efficient and safer method of managing 
HIV/AIDS infection. Taking this clinical procedure further to clinical trial stage will definitely push us further 
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towards achieving the goal of curing HIV/AIDS infection that the health community has long struggled with. 
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